Skip to main content
SpringerLink
Log in

Fibrinolysis

  • Chapter
Clinical Chemistry

  • 314 Accesses

Abstract

Over the last several years, there has been an explosion of new discoveries in the field of fibrinolysis. The cDNA and consequently the primary amino sequences of most of the components of the fibrinolytic system have been determined (reviewed in part in 1), the regulation of gene expression by hormones, growth factors and phorbolesters extensively studied, the enzyme kinetics of plasminogen activation worked out (reviewed in 2), two major plasminogen activator inhibitors characterized (reviewed in 3, 4), the role of plasminogen activators in cancerigenesis and the regulation of pericellular proteolysis explored (reviewed in 5, 6), correlations between a deficient fibrinolytic activity and the incidence of idiopathic deep vein thrombosis established and major progress in thrombolytic therapy achieved (reviewed in 2, 7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blasi F, Riccio A, Sebastio G. Human plasminogen activators. Genes and proteins structure. In: Blasi F, ed. Human Genes and Diseases. New York: John Wiley & Sons Ltd. 1986: 377–414.

    Google Scholar 

  2. Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77–94.

    Article  CAS  Google Scholar 

  3. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood, 1987; 69: 381–387.

    CAS  Google Scholar 

  4. Kruithof EKO. Inhibitors of plasminogen activators. In: Kluft C, ed. Tissue-type plasminogen activator: Physiological and Clinical Aspects. Boca Raton: CRC Press 1987; in press.

    Google Scholar 

  5. Danø, K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–266.

    Article  Google Scholar 

  6. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35–65.

    CAS  Google Scholar 

  7. Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986; 67: 1529–1541.

    CAS  Google Scholar 

  8. Muellertz S. Fibrinolysis. General aspects, characteristic features and perspectives. Fibrinolysis 1987; 1: 3–12.

    Article  CAS  Google Scholar 

  9. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 1984; 10: 18–23.

    Article  CAS  Google Scholar 

  10. Young CL, Barker WC, Tomaselli CM, Dayhoft MO. Serine proteases. In: Atlas of Protein Sequence and Structure. Silver Spring: The National Biomedical Research Foundation 1978: 73–93.

    Google Scholar 

  11. Malinowski DP, Sadler JE, Davie EW. Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen. Biochemistry 1984; 23: 4243–4250.

    Article  CAS  Google Scholar 

  12. Swisshelm K, Dyer K, Sadler E, Disteche C. Localisation of the plasminogen gene (plg) to the distal portion of the long arm of chromosome 6 by in situ hybridization. Cytogenet Cell Genet 1985; 40: 756.

    Google Scholar 

  13. Lijnen HR, Collen D. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemost 1982; 8: 2–10.

    Article  CAS  Google Scholar 

  14. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77–89.

    CAS  Google Scholar 

  15. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249–4256.

    CAS  Google Scholar 

  16. Varadi A, Patthy L. Beta(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E. Biochemistry 1984; 23: 2108–2112.

    Article  CAS  Google Scholar 

  17. Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214–221.

    Article  CAS  Google Scholar 

  18. Edlund T, Ny T, Rånby M, et al. Isolation of cDNA sequences coding for a part of human tissue plasminogen activator. Proc Natl Acad Sci USA 1983; 80: 349–352.

    Article  CAS  Google Scholar 

  19. Fisher R, Waller EK, Grossi G, Thompson D, Tizard R, Schleuning W.-D. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5′ flanking region. J Biol Chem 1985; 260: 11223–11230.

    CAS  Google Scholar 

  20. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: Correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 1984; 81: 5355–5359.

    Article  CAS  Google Scholar 

  21. Rajput B, Degen SF, Reich E, et al. Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science 1985; 230: 672–674.

    Article  CAS  Google Scholar 

  22. Verheijen JH, Visse R, Wijnen JTh, Chang GTG, Kluft C, Meera Khan P. Assignment of the human tissue-type plasminogen activator gene (PLAT) to chromosome 8. Hum Genet 1986; 72: 153–156.

    Article  CAS  Google Scholar 

  23. Wallen P, Pohl G, Bergsdorf N, Rånby M, Ny T, Jornvall H. Structural characterization of tissue plasminogen activator purified by immunosorbent chromatography. In: Davidson JF, Bachman F, Bouvier CA, Kruithof EKO, eds. Progress in Fibrinolysis. Edinburgh: Churchill Livingstone, 1983; Vol 6: 338–343.

    Google Scholar 

  24. Dodd I, Fears R, Robinson JH. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemost 1986; 55: 94–97.

    CAS  Google Scholar 

  25. Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098–3102.

    CAS  Google Scholar 

  26. Van Zonneveld A-J, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci USA 1986; 83: 4670–4674.

    Article  Google Scholar 

  27. Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. J Biol Chem 1986; 261: 14214–14218.

    Google Scholar 

  28. Verheijen JH, Caspers MPM, Chang GTG, De Munk GAW, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. Embo J 1986; 5: 3525–3530.

    CAS  Google Scholar 

  29. Kagitani H, Tagawa M, Hatanaka K, et al. Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity. Febs Lett 1985; 189: 145–149.

    Article  CAS  Google Scholar 

  30. Ehrlich HJ, Bang NU, Little SP, et al. Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. Fibrinolysis 1987; 1: 75–81.

    Article  CAS  Google Scholar 

  31. Rijken DC, Emeis JJ, Gerwig GJ. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells. Thromb Haemost 1985; 54: 788–791.

    CAS  Google Scholar 

  32. Bachmann F, Kruithof EKO. Tissue plasminogen activator: Chemical and physiological aspects. Semin Thromb Hemost 1984; 10: 6–17.

    Article  CAS  Google Scholar 

  33. Rijken DC, Wijngaards G, Collen D. Tissue-type plasminogen activator from human tissue and cell cultures and its occurrence in plasma. In: Collen D, Lijnen HR, Verstraete M., eds. Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Edinburgh: Churchill Livingstone 1985: 15–30.

    Google Scholar 

  34. Rånby M, Wallén P. Enzymatic properties of tissue-type plasminogen activator. In: Collen D, Lijnen HR, Verstraete M., eds. Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Edinburgh: Churchill Livingstone 1985: 31–48.

    Google Scholar 

  35. Norrman B, Wallen P, Rånby M. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem 1985; 149: 193–200.

    Article  CAS  Google Scholar 

  36. Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW, Verheijen JH. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 1983; 748: 86–92.

    Article  CAS  Google Scholar 

  37. Suenson E, Petersen LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 1986; 870: 510–519.

    Article  CAS  Google Scholar 

  38. Tran-Thang C, Kruithof EKO, Atkinson J, Bachmann F. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem 1986; 160: 599–604.

    Article  CAS  Google Scholar 

  39. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338–343.

    Article  CAS  Google Scholar 

  40. Collen D. Report of the meeting of the subcommittee on fibrinolysis, (ICTH), Jerusalem, Israel. Thromb Haemost 1986; 56: 415–416.

    Google Scholar 

  41. Kruithof EKO, Vassalli J-D, Schleuning W-D, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261: 11207–11213.

    CAS  Google Scholar 

  42. Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost 1985; 53: 134–136.

    CAS  Google Scholar 

  43. Verstraete M, Su CAPF, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost 1986; 56: 1–5.

    CAS  Google Scholar 

  44. Verstraete M, Bounameaux H, De Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506–512.

    CAS  Google Scholar 

  45. Gunzler WA, Steffens GJ, Ötting F, Kim SM, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem 1982; 363: 1155–1165.

    Article  CAS  Google Scholar 

  46. Steffens GJ, Günzler WA, Otting F, Frankus E, Flohe L. The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z Physiol Chem 1982; 363: 1043–1058.

    Article  CAS  Google Scholar 

  47. Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31–38.

    Article  CAS  Google Scholar 

  48. Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261: 1267–1273.

    CAS  Google Scholar 

  49. Cajot J-F, Kruithoff EKO, Schleuning W-D, Sordat B, Bachmann F. Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986; 38: 719–727.

    Article  CAS  Google Scholar 

  50. Corti A, Nolli ML, Soffientini A, Cassani G. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells. Thromb Haemost 1986; 56: 219–224.

    CAS  Google Scholar 

  51. Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem 1986; 261: 1274–1278.

    CAS  Google Scholar 

  52. Darras V, Thienpont M, Stump DC, Collen C. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1986; 56: 411–414.

    CAS  Google Scholar 

  53. Holmes WE, Pennica D, Blaber M, et al. Cloning and expression of the gene for pro-urokinase in Escherichia coli. Biotechnol 1985; 3: 923–929.

    Article  CAS  Google Scholar 

  54. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci USA 1984; 81: 4727–4731.

    Article  CAS  Google Scholar 

  55. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F. The human urokinase plasminogen activator gene and its promoter. Nucleic Acids Res 1985; 13: 2759–2771.

    Article  CAS  Google Scholar 

  56. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem, 1986; 261: 3486–3489.

    CAS  Google Scholar 

  57. Schaller J, Nick H, Rickli E, Gillessen D, Lergier W, Studer RO. The two-chain structure of human low molecular weight urinary urokinase, evidenced by sequence analysis. In: Davidson JF, Bachmann F, Bouvier CA, Kruithof EKO, eds. Progress in Fibrinolysis. Edinburgh: Churchill Livingstone 1983; Vol VI: 348–352.

    Google Scholar 

  58. Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120–17126.

    CAS  Google Scholar 

  59. Rijken DC, Binnema JD, Los P. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 761–768.

    Article  CAS  Google Scholar 

  60. Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377–12381.

    CAS  Google Scholar 

  61. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase — A demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22–26.

    CAS  Google Scholar 

  62. Nielsen LS, Hansen JG, Skriver L, et al. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 21: 6410–6415.

    Article  CAS  Google Scholar 

  63. Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261: 1253–1258.

    CAS  Google Scholar 

  64. Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. II. Kinetics. J Biol Chem 1986; 261: 1259–1266.

    CAS  Google Scholar 

  65. Gurewich V, Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: Relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769–772.

    CAS  Google Scholar 

  66. Pannell R, Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215–1223.

    CAS  Google Scholar 

  67. Kasai S, Arimura H, Nishida M, Suyama T. Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells. Cell Struct Funct 1985; 10: 151–159.

    Article  CAS  Google Scholar 

  68. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731–1739.

    Article  CAS  Google Scholar 

  69. Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase — I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemost 1984; 52: 19–23.

    CAS  Google Scholar 

  70. Collen D, Stassen JM, Blaber M, Winkler N, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase — III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 1984; 52: 27–30.

    CAS  Google Scholar 

  71. Matsuo O, Bando H, Okada K, et al. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model. Thromb Res 1986; 42: 187–194.

    Article  CAS  Google Scholar 

  72. Lijnen HR, Van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986; 884: 402–408.

    CAS  Google Scholar 

  73. Stump DC, Stassen JM, Demarsin E, Collen D. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator. Blood 1987; 69: 592–596.

    CAS  Google Scholar 

  74. Van de Werf F, Jang IK, Collen D. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis. J Cardiovasc Pharmacol 1987; 9: 91–93.

    Google Scholar 

  75. Van de Werf F, Vanhaecke J, De Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066–1070.

    Article  Google Scholar 

  76. Kristensen P, Larsson L-I, Nielsen LS, Grondahl-Hansen J, Andreasen PA, Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett 1984; 168: 33–37.

    Article  CAS  Google Scholar 

  77. Larsson L-I, Skriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Danø) K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984; 98: 894–903.

    Article  CAS  Google Scholar 

  78. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86–92.

    Article  CAS  Google Scholar 

  79. Del Rosso M, Dini G, Fibbi G. Receptors for plasminogen activator, urokinase, in normal and rous sarcoma virus-transformed mouse fibroblasts. Cancer Res 1985; 45: 630–636.

    Google Scholar 

  80. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939–4943.

    Article  CAS  Google Scholar 

  81. Bajpai A, Baker JB. Urokinase binding sites on human foreskin cells. Evidence for occupancy with endogenous urokinase. Biochem Biophys Res Commun 1985; 133: 994–1000.

    Article  CAS  Google Scholar 

  82. Blasi F, Stoppelli MP, Cubellis MV. The receptor for urokinase-plasminogen activator. J Cell Biochem 1986; 32: 179–186.

    Article  CAS  Google Scholar 

  83. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain pro-urokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986; 261: 15819–15822.

    CAS  Google Scholar 

  84. Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Hemost 1987; 13: 1–4.

    Article  CAS  Google Scholar 

  85. Fujikawa K, McMullen BA. Amino acid sequence of human β-factor XIIa. J Biol Chem 1983; 258: 10924–10933.

    CAS  Google Scholar 

  86. McMullen BA, Fujikawa K. Amino acid sequence of the heavy chain of human a-factor XIIa (activated Hageman factor). J Biol Chem 1985; 260: 5328–5341.

    CAS  Google Scholar 

  87. Que BG, Davie EW. Characterization of a cDNA coding for human factor XII (Hageman factor). Biochemistry 1986; 25: 1525–1528.

    Article  CAS  Google Scholar 

  88. Cool DE, Edgell C-JS, Louie GV, Zoller MJ, Brayer GD, MacGillivray RTA. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of β-factor XIIa. J Biol Chem 1985; 260: 13666–13676.

    CAS  Google Scholar 

  89. Takagaki Y, Kitamura N, Nakanishi S. Cloning and sequence analysis of cDNA’s for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem 1985; 260: 8601–8609.

    CAS  Google Scholar 

  90. Van Iwarden F, Bouma BN. Role of high molecular weight kininogen in contact activation. Semin Thromb Hemost 1987; 13: 15–24.

    Article  Google Scholar 

  91. Mannhalter ChH. Biochemical and functional properties of factor XI and prekallikrein. Semin Thromb Hemost 1987; 13: 25–35.

    Article  CAS  Google Scholar 

  92. Chung DW, Fujikawa K, McMullen BA, Davie EW. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410–2417.

    Article  CAS  Google Scholar 

  93. Sumi Y, Nakamura Y, Aoki N, Sakai M, Muramatsu M. Structure of the carboxyl-terminal half of human α 2-plasmin inhibitor deduced from that of cDNA. J Biochem 1986; 100: 1399–1402.

    CAS  Google Scholar 

  94. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human α 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987; 262: 1659–1664.

    CAS  Google Scholar 

  95. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10: 24–41.

    Article  CAS  Google Scholar 

  96. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α 2-plasmin inhibitor. Blood 1987; 69: 446–453.

    CAS  Google Scholar 

  97. Ichinose A, Aoki N. The initiation of fibrinolysis in α 2-plasmin inhibitor deficient plasma. Role df fibrin. Thromb Res 1986; 41: 847–854.

    Article  CAS  Google Scholar 

  98. Sottrup-Jensen L, Stepanik TM, Kristensen T, et al. Primary structure of human α 2-macroglobulin. V. The complete structure. J Biol Chem 1984; 259: 8318–8327.

    CAS  Google Scholar 

  99. Kan CC, Solomon E, Belt KT, Chain AC, Hiorns LR, Fey G. Nucleotide sequence of cDNA encoding human α 2-macroglobulin and assignment of the chromosomal locus. Proc Natl Acad Sci USA 1985; 82: 2282–2286.

    Article  CAS  Google Scholar 

  100. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655–709.

    Article  CAS  Google Scholar 

  101. Kruithof EKO, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In: Davidson JF, Bachmann F, Bouvier CA, Kruithof EKO, eds. Progress in Fibrinolysis. Edinburgh: Churchill Livingstone 1983; Vol VI: 362–366.

    Google Scholar 

  102. Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377–387.

    Article  CAS  Google Scholar 

  103. Esnard F, Dupuy E, Dosne AM, Bodevin E. Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein. Thromb Haemost 1982; 47: 128–131.

    CAS  Google Scholar 

  104. Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956–2960.

    Article  CAS  Google Scholar 

  105. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804–6808.

    Article  CAS  Google Scholar 

  106. Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99–110.

    CAS  Google Scholar 

  107. Sprengers ED, Verheijen JH, Van Hinsbergh VWM, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163–170.

    CAS  Google Scholar 

  108. Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914–14921.

    Google Scholar 

  109. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436.

    Article  CAS  Google Scholar 

  110. Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111–118.

    CAS  Google Scholar 

  111. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907–913.

    CAS  Google Scholar 

  112. Verheijen JH, Chang GT, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392–395.

    CAS  Google Scholar 

  113. Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644–3647.

    CAS  Google Scholar 

  114. Wagner OF, Binder BR. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J Biol Chem 1986; 261: 14474–14481.

    CAS  Google Scholar 

  115. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776–6780.

    Article  CAS  Google Scholar 

  116. Pannekoek H, Veerman H, Lambers H, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5: 2539–2544.

    CAS  Google Scholar 

  117. Ginsburg D, Zeheb R, Yang AY, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673–1680.

    Article  CAS  Google Scholar 

  118. Wun TC, Kretzmer KK. cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Lett 1987; 210: 11–16.

    Article  CAS  Google Scholar 

  119. Carrell RW, Jeppsson J-O, Laurell C-B, et al. Structure and variation of human α 1-antitrypsin. Nature 1982; 298: 329–334.

    Article  CAS  Google Scholar 

  120. Kruithof EKO, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost 1986; 55: 65–69.

    CAS  Google Scholar 

  121. Andreasen PA, Riccio A, Welinder KG, et al. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213–218.

    Article  CAS  Google Scholar 

  122. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465–1472.

    Article  CAS  Google Scholar 

  123. Kruithof EKO, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 1986; 55: 201–205.

    CAS  Google Scholar 

  124. Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325–329.

    CAS  Google Scholar 

  125. Sprengers ED, Princen HMG, Kooistra T, Van Hinsbergh VWM. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751–758.

    CAS  Google Scholar 

  126. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581–11587.

    CAS  Google Scholar 

  127. Levin EG. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 1986; 67: 1309–1313.

    CAS  Google Scholar 

  128. Kooistra T, Sprengers ED, Van Hinsbergh VWM. Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem J 1986; 239: 497–503.

    CAS  Google Scholar 

  129. Lawrence DA, Loskutoff DJ. Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 1986; 25: 6351–6355.

    Article  CAS  Google Scholar 

  130. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165–169.

    Article  CAS  Google Scholar 

  131. Levin EG, Stern DM, Nawroth PP, et al. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 1986; 56: 115–119.

    CAS  Google Scholar 

  132. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97–104.

    CAS  Google Scholar 

  133. Loskutoff DJ, Roegner K, Erickson LA, et al. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells. Thromb Haemost 1986; 55: 8–11.

    CAS  Google Scholar 

  134. Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer-Laszuk R, Gelehrter TD. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1986; 9: 4352–4357.

    Google Scholar 

  135. Laiho M. Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-β. J Cell Biol 1986; 103: 2403–2410.

    Article  CAS  Google Scholar 

  136. Crutchley DJ, Conanan LB. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1986; 261: 154–159.

    CAS  Google Scholar 

  137. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75:818–824.

    Article  CAS  Google Scholar 

  138. Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253–254.

    Article  CAS  Google Scholar 

  139. Vassalli J-D, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of pro-urokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653–1668.

    Article  CAS  Google Scholar 

  140. Kopitar M, Rozman B, Babnik J, Turk V, Mullins DE, Wun T-C. Human leucocyte urokinase inhibitor. Purification, characterization and comparative studies against different plasminogen activators. Thromb Haemost 1985; 54: 750–755.

    CAS  Google Scholar 

  141. Chapman HA, Stone OL. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. Biochem J 1985; 230: 109–116.

    CAS  Google Scholar 

  142. Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987; 165: 320–339.

    Article  CAS  Google Scholar 

  143. Astedt B, Lecander I, Brodin T, Lundblad A, Loew K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 1985; 53: 122–125.

    CAS  Google Scholar 

  144. Ye RD, Wun T-CJ, Sadler JE. Characterization of cDNA for a plasminogen activator inhibitor from human placenta. Circulation 1986; 1: 988.

    Google Scholar 

  145. Schleuning WD, Medcalf RL, Hession K, Rothenbuehler R, Kruithof EKO. Plasminogen activator inhibitor 2: molecular cloning and regulation of gene transcription during phorbol ester mediated differentiation of U-937 human histiocytic lymphoma cells (submitted).

    Google Scholar 

  146. Kruithof EKO, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460–466.

    CAS  Google Scholar 

  147. Lecander I, Åstedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221–228.

    Article  CAS  Google Scholar 

  148. Åstedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Hemost 1986; 56: 63–65.

    Google Scholar 

  149. Åstedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand J Clin Lab Invest 1985; 45: 429–435.

    Google Scholar 

  150. Salvesen GS, Catanese JJ, Kress LF, Travis J. Primary structure of the reactive site of human Cl-inhibitor. J Biol Chem 1985; 260: 2432–2436.

    CAS  Google Scholar 

  151. Tosi M, Duponchel C, Bourgarel P, Colomb M, Meo T. Molecular cloning of human Cl inhibitor: Sequence homologies with α 1-antitrypsin and other members of the serpins superfamily. Gene 1986; 42: 265–272.

    Article  CAS  Google Scholar 

  152. Bock, SC, Skriver K, Nielsen E, et al. Human Cl inhibitor: Primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292–4301.

    Article  CAS  Google Scholar 

  153. Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986; 25: 2220–2225.

    Article  CAS  Google Scholar 

  154. Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. J Biol Chem 1980; 255: 10214–10222.

    CAS  Google Scholar 

  155. Ichinose A, Mimuro J, Koide T, Aoki N. Histidine-rich glycoprotein and α 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. Thromb Res 1984; 33: 401–407.

    Article  CAS  Google Scholar 

  156. Silverstein RL, Leung LLK, Nachman RL. Thrombospondin: A versatile multifunctional glycoprotein. Arteriosclerosis 1986; 6: 245–253.

    Article  CAS  Google Scholar 

  157. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: Tetranectin. Eur J Biochem 1986; 156: 327–333.

    Article  CAS  Google Scholar 

  158. Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood 1985; 66:399–401.

    CAS  Google Scholar 

  159. Tran-Thang C, Kruithof EKO, Bachmann F. The mechanism of in vitro clot lysis induced by vascular plasminogen activator. Blood 1984; 63: 1331–1337.

    CAS  Google Scholar 

  160. Kimura S, Aoki N. Cross-linking site in fibrinogen for α 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591–15595.

    CAS  Google Scholar 

  161. Harpel PC, Chang T-S, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 1985; 260: 4432–4440.

    CAS  Google Scholar 

  162. Tran-Thang C, Kruithof EKO, Bachmann F. Tissue-type plasminogen activator increases the binding of Glu-plasminogen to clots. J Clin Invest 1984; 74: 2009–2016.

    Article  CAS  Google Scholar 

  163. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Sci USA 1985; 82: 1121–1125.

    Article  CAS  Google Scholar 

  164. Van Hinsbergh VWM, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444–451.

    Google Scholar 

  165. De Fouw NJ, Haverkate F, Bertina RM, Koopman J, Van Wijngaarden A, Van Hinsbergh VWM. The cofactor role of protein S in the acceleration of whole clot lysis by activated protein C in vitro. Blood 1986; 67: 1189–1192.

    Google Scholar 

  166. D’Angelo A, Lockhart MS, D’Angelo SV, Taylor FB. Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets. Blood 1987; 69: 231–237.

    Google Scholar 

  167. Aznar J, Dasi A, Espana F, Estellés A. Fibrinolytic study in a homozygous protein C deficient patient. Thromb Res 1986; 42: 313–322.

    Article  CAS  Google Scholar 

  168. Hauert J, Bachmann F. In vitro clot lysis induced by single-chain urokinase (scu-PA) and activation of the contact phase system. Thromb Haemost 57, abstract, XI Int Congr Thromb Haemost, Bruxelles, 1987.

    Google Scholar 

  169. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50–68.

    Article  CAS  Google Scholar 

  170. Hauert J, Bachmann F. Prourokinase in the euglobulin fractions. Thromb Hemost 1985; 54: 122.

    Google Scholar 

  171. Knot EAR, Ten Cate JW, Lamping RJ, Gie LK. α 2-Antiplasmin: Functional characterization and metabolism in a heterozygote deficient patient. Thromb Haemost 1986; 55: 375–378.

    CAS  Google Scholar 

  172. Scharrer IM, Wohl RC, Hach V, Sinio L, Boreisha I, Robbins KC. Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. Thromb Haemost 1986; 55: 396–401.

    CAS  Google Scholar 

  173. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248–255.

    Article  CAS  Google Scholar 

  174. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67–72.

    CAS  Google Scholar 

  175. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453–1456.

    Article  CAS  Google Scholar 

  176. Stalder M, Hauert J, Kruithof EKO, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: Electrophoretic-zymographic analysis of free and complexed v-PA. Br J Haematol 1985; 61: 169–176.

    Article  CAS  Google Scholar 

  177. Marbet GA, Duckert F, Biland L, Widmer LK. Quantitative and qualitative Hämostaseveränderungen bei 373 Patienten mit rezidivierenden Venenthrombosen. Schweiz med Wschr 1985; 115: 1505–1506.

    CAS  Google Scholar 

  178. Jørgensen M, Bonnevie-Nielsen V. Increased concentration of the fastacting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175–180.

    Article  Google Scholar 

  179. Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127–130.

    CAS  Google Scholar 

  180. Paramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573–574.

    Article  CAS  Google Scholar 

  181. Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563.

    Article  CAS  Google Scholar 

  182. D’Angelo A, Kluft C, Verheijen JH, Rijken DC, Mozzi E, Mannucci PM. Fibrinolytic shut-down after surgery: Impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985; 15: 308–312.

    Article  Google Scholar 

  183. Kluft C, Verheijen JH, Jie AFH, et al. The postoperative fibrinolytic shutdown: A rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605–610.

    Article  CAS  Google Scholar 

  184. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160–2165.

    Google Scholar 

  185. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250–253.

    Article  CAS  Google Scholar 

  186. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523–530.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lab Centrale d’Haematologie, Central Hospitalier Vaudois, Switzerland

    F. Bachman

Authors
  1. F. Bachman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospital Rotterdam, Rotterdam, The Netherlands

    N. C. den Boer  & B. Leijnse  & 

  2. University Hospital for Children and Youth, Utrecht, The Netherlands

    C. van der Heiden

  3. University Hospital Leiden, Leiden, The Netherlands

    J. H. M. Souverijn

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Plenum Press, New York

About this chapter

Cite this chapter

Bachman, F. (1989). Fibrinolysis. In: den Boer, N.C., van der Heiden, C., Leijnse, B., Souverijn, J.H.M. (eds) Clinical Chemistry. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0753-2_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0753-2_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8065-1

  • Online ISBN: 978-1-4613-0753-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation